Multidisciplinary

Top Medical News
Homocysteine tied to spinal osteoarthritis prevalence in postmenopausal women
22 minutes ago
Circulating homocysteine and C677T variant in methylenetetrahydrofolate reductase (MTHFR) appear to influence the prevalence rate and ensuing progression of spinal osteoarthritis (OA), respectively, in postmenopausal women, a study has shown.
Saving the heart: “Statins are effective”—supports Malaysian study
2 hours ago
Using artificial intelligence-powered software to deliver personalized behavioural nudges helps improve patient adherence to statins, a new trial has found.
Heart failure after first heart attack associated with increased cancer risk
3 hours ago
Tolvaptan does not seem to be a cost-effective option for long-term treatment of chronic heart failure, reports a recent Japan study.
Amyloid burden spurs white matter degradation in cognitively normal elderly
20 hours ago
The progression of white matter changes in cerebral small vessel disease does not seem to be different between aspirin- and cilostazol-treated patients, a study has found.
Statins help preserve liver function in chronic liver disease
Pearl Toh, 22 hours ago
Statins can help preserve liver function in patients with chronic liver disease, according to two studies presented at AASLD 2021— showing that not only are statins protective for the heart, but also for the liver.
Tonsillectomy may lower risk of psoriasis
23 hours ago
Patients who received tonsillectomy have a lower risk of psoriasis, reports a study, following adjustment for baseline characteristics, comorbidities, and medical confounders relative to a comparison group.
Spinal anaesthesia no better than general anaesthesia for hip surgery
Roshini Claire Anthony, Yesterday

In patients undergoing surgery for hip fracture, the use of spinal anaesthesia was not better than general anaesthesia in terms of post-surgical outcomes such as death and mobility, according to results of the REGAIN* trial presented at Anesthesiology 2021.

Special Reports
EMPEROR-Preserved: The first successful trial to improve outcomes in HFpEF
18 Nov 2021
Heart failure with preserved ejection fraction (HFpEF) represents a significant unmet medical need. The EMPEROR-Preserved trial aimed to assess the impact of empagliflozin on cardiovascular outcomes in patients with HFpEF. On 27 August 2021, during the hotline session of the 2021 ESC Virtual Congress, the main results of the EMPEROR-Preserved trial were presented by Professor Stefan Anker, principal investigator of the study, and heart failure specialist at Charité Berlin, Germany.
NOACs in nonvalvular atrial fibrillation with multimorbidity: Where does apixaban stand?
02 Nov 2021
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice, affecting millions of people globally. Stroke is one of its devastating complications, with the risk steeply increasing with advancing age. Additionally, AF is associated with more than a tripling of the risk of systemic embolic (SE) events. [J Am Heart Assoc 2020;9:e016724]
Fighting oxidation: new insights in pathogenesis and management of atopic dermatitis
01 Nov 2021
Atopic dermatitis (AD) is a chronic inflammatory skin condition that affects quality of life for adults and children worldwide. At a recent Menarini expert meeting, Dr Benji Teoh Tze-Yuen, head of dermatology at Hospital Selayang, and Professor Dr Giovanni Pellacani, dermatology department chairman at University of Rome, Italy, discussed new understandings of the roleoxidative stress (OS) plays in AD pathophysiology, as well as the potential role of antioxidants such as furfuryl palmitate in contemporary paradigms of AD treatment.
Kids hard-hit by Delta; which ART performs best?
Elvira Manzano, 24 Oct 2021
That COVID-19 mostly spared children might be changing. The Delta variant has taken a severe, unthinkable toll on kids – at least in Arkansas, US, reports an expert at IDWeek 2021.
Rapid antigen test: Don’t let perfect be the enemy of good
Pearl Toh, 23 Oct 2021
While rapid antigen test is less sensitive than conventional nucleic acid amplification test (NAAT) such as RT-PCR* in detecting SARS-CoV-2 virus, “a test does not have to be perfect to be clinically useful,” said Professor Angela Caliendo during a session in IDWeek 2021 — echoing the maxim that perfect should not be the enemy of good in the pandemic era.
ID NOW rapid molecular assay an effective COVID-19 test for kids
Roshini Claire Anthony, 20 Oct 2021

A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.

Conference Reports
Statins help preserve liver function in chronic liver disease
Pearl Toh, 27 Nov 2021
Statins can help preserve liver function in patients with chronic liver disease, according to two studies presented at AASLD 2021— showing that not only are statins protective for the heart, but also for the liver.
Spinal anaesthesia no better than general anaesthesia for hip surgery
Roshini Claire Anthony, 27 Nov 2021

In patients undergoing surgery for hip fracture, the use of spinal anaesthesia was not better than general anaesthesia in terms of post-surgical outcomes such as death and mobility, according to results of the REGAIN* trial presented at Anesthesiology 2021.

Methylprednisolone improves major kidney outcomes in patients with IgAN
Elaine Soliven, 26 Nov 2021
Treatment with methylprednisolone reduces the risk of kidney composite outcomes, including kidney failure, 40 percent decline in eGFR, or death due to kidney disease, in patients with IgA nephropathy (IgAN), according to the TESTING* study presented at ASN Kidney Week 2021.
6-month single antiplatelet regimen after DAPT post-PCI may reduce GI injury
Roshini Claire Anthony, 25 Nov 2021

Among patients who received 6 months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), switching to a single antiplatelet therapy (SAPT) regimen for another 6 months resulted in less gastrointestinal (GI) injury than continuing DAPT, results of the OPT-PEACE trial showed.

Lumasiran reduces plasma oxalate in advanced PH1
Elvira Manzano, 25 Nov 2021
Treatment with the RNAi therapeutic lumasiran led to a significant reduction in plasma oxalate and pre-dialysis oxalate levels in patients with advanced primary hyperoxaluria type 1 (PH1), according to the 6-month primary analysis of phase III ILLUMINATE-C trial presented at ASN Kidney Week 2021.
Oral daprodustat on par with ESA for anaemia in CKD
Pearl Toh, 24 Nov 2021
The oral HIF-PHI* daprodustat was noninferior to standard treatment with erythropoiesis-stimulating agents (ESAs) for increasing haemoglobin levels to within target range, without increasing cardiovascular (CV) risk in patients with anaemia due to chronic kidney disease (CKD), regardless of whether they were dialysis dependent or not, according to the phase III ASCEND-D/-ND trials presented at ASN 2021.
Dupilumab benefits in EoE sustained through 52 weeks
Pearl Toh, 23 Nov 2021
The anti–interleukin (IL)-4/-13 antibody dupilumab led to sustained improvements across symptomatic, histologic, and endoscopic measures of eosinophilic oesophagitis (EoE) out to 52 weeks, according to additional data from the LIBERTY EoE TREET trial presented at ACG 2021.